{
    "id": 2949,
    "fullName": "FLT3 act mut",
    "impact": "unknown",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 act mut indicates that this variant results in a gain of function in the Flt3 protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "act mut",
    "createDate": "01/15/2015",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6585,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and SGI-1776 were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 4184,
                "therapyName": "Palbociclib + SGI-1776",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5701,
                    "pubMedId": 27099147,
                    "title": "Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27099147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6583,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Quizartinib (AC220) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 4161,
                "therapyName": "Palbociclib + Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5701,
                    "pubMedId": 27099147,
                    "title": "Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27099147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6576,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) blocked growth, induced apoptosis, and inhibited STAT activation in human FLT3-ITD positive human acute myeloid leukemia cells in culture (PMID: 27099147).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5701,
                    "pubMedId": 27099147,
                    "title": "Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27099147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2531,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, 59% (13/22) of acute myeloid leukemia patients harboring FLT3 activating mutations achieved complete remission following treatment with Sutent (sunitinib) in combination with Cytarabine and Daunorubicin (PMID: 25818407).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 2923,
                "therapyName": "Cytarabine + Daunorubicin + Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3256,
                    "pubMedId": 25818407,
                    "title": "A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25818407"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6581,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TCS-359 inhibited growth of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 2615,
                "therapyName": "TCS 359",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5701,
                    "pubMedId": 27099147,
                    "title": "Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27099147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8849,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a FLT3-ITD positive human acute myeloid leukemia cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23270925).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 960,
                "therapyName": "VS-5584",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 351,
                    "pubMedId": 23270925,
                    "title": "VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23270925"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3584,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, relapsed or refractory acute myeloid leukemia patients harboring FLT3 activating mutations without a history of FLT3 therapy demonstrated a significantly greater overall survival and event free survival compared to those that had prior FLT3 therapy when treated with Crenolanib (ASH meeting, Dec 2014, abstract #389).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3856,
                    "pubMedId": null,
                    "title": "Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations",
                    "url": "https://ash.confex.com/ash/2014/webprogram/Paper74499.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6579,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 4160,
                "therapyName": "Palbociclib + TCS 359",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5701,
                    "pubMedId": 27099147,
                    "title": "Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27099147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2532,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX3397 inhibited FLT3 autophosphorylation in leukemia cells overexpressing FLT3 or harboring FLT3 activating mutations, and inhibited growth of leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (ASH Annual Meeting Abstracts 2011 118: 3632).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3257,
                    "pubMedId": null,
                    "title": "The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML",
                    "url": "http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3632?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=PLX3397&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6584,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and tandutinib (MLN518) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",
            "molecularProfile": {
                "id": 2774,
                "profileName": "FLT3 act mut"
            },
            "therapy": {
                "id": 4162,
                "therapyName": "Palbociclib + Tandutinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5701,
                    "pubMedId": 27099147,
                    "title": "Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27099147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2774,
            "profileName": "FLT3 act mut",
            "profileTreatmentApproaches": [
                {
                    "id": 3996,
                    "name": "FLT3 Inhibitor",
                    "profileName": "FLT3 act mut"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}